Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
BioNTech SE
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Bristol-Myers Squibb
Eli Lilly and Company
Pheon Therapeutics
AstraZeneca
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
Instil Bio
AstraZeneca
BeOne Medicines
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Exelixis
BeOne Medicines
Astellas Pharma Inc
Institut Claudius Regaud
National Institutes of Health Clinical Center (CC)
BioNTech SE
Kura Oncology, Inc.
Zymeworks BC Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
AbbVie
Johnson & Johnson Enterprise Innovation Inc.
Eli Lilly and Company
Iambic Therapeutics, Inc
Amgen
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
EMD Serono
Plexium, Inc.
The Methodist Hospital Research Institute
OncoC4, Inc.
Deciphera Pharmaceuticals, LLC
Revolution Medicines, Inc.
Novartis
Exscientia AI Limited
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.